PDF(Pubmed)
Abstract：
Nasal congestion is a common issue stemming from various factors such as allergies and anatomical variations. Allergic rhinitis frequently leads to nasal congestion. The pathophysiology involves inflammation, swelling, and mucus production in the nasal mucosa. Multiple treatments are available, including oral phenylephrine, an over-the-counter or prescription option. However, the effectiveness and safety of phenylephrine have been subjects of debate. This systematic review aims to provide an updated perspective on the efficacy of oral phenylephrine versus placebo in addressing nasal congestion in adults. We conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines, a systematic review involving searches on PubMed, Cochrane, and Scopus databases. Inclusion/exclusion criteria were defined to identify high-quality studies. The focus was on randomized controlled trials (RCTs) and case-control studies published in English between 1998 and 2023, involving adult populations. The interventions compared oral phenylephrine with placebo or standard care, with outcomes centering on changes in nasal congestion symptoms and nasal airway resistance. We identified four articles that met the criteria. These studies exhibited varied designs and populations. The findings consistently indicated that phenylephrine was not more effective than a placebo in relieving nasal congestion. This systematic review demonstrates that oral phenylephrine did not offer substantial relief from nasal congestion compared to a placebo in adults. The studies featured diverse designs, yet the prevailing conclusion was that phenylephrine\'s efficacy was limited. Safety assessments showed no life-threatening adverse events, with common side effects including headaches and mild discomfort. In summary, this systematic review indicates that oral phenylephrine is not significantly more effective than a placebo in alleviating nasal congestion in adults. Clinicians should explore alternative treatment options, considering the review\'s limitations. Additional research may be needed to clarify the role of oral phenylephrine in managing nasal congestion.
摘要：
鼻充血是一个常见的问题，源于各种因素，如过敏和解剖变异。过敏性鼻炎常导致鼻塞。病理生理学涉及炎症，肿胀,和鼻粘膜中的粘液产生。有多种治疗方法,包括口服去氧肾上腺素,非处方药或处方选择。然而,去氧肾上腺素的有效性和安全性一直是争论的主题.本系统综述旨在提供关于口服去氧肾上腺素与安慰剂治疗成人鼻塞疗效的最新观点。我们遵循2020年系统评价和荟萃分析(PRISMA)指南的首选报告项目，涉及在PubMed上搜索的系统审查，科克伦,和Scopus数据库。定义纳入/排除标准以确定高质量的研究。重点是1998年至2023年之间以英语发表的随机对照试验（RCT）和病例对照研究，涉及成年人群。干预措施比较了口服去氧肾上腺素与安慰剂或标准治疗，以鼻塞症状和鼻气道阻力的变化为中心。我们确定了四篇符合标准的文章。这些研究展示了不同的设计和群体。研究结果一致表明，去氧肾上腺素在缓解鼻塞方面并不比安慰剂更有效。该系统评价表明，与安慰剂相比，口服去氧肾上腺素不能实质性缓解成人的鼻塞。这些研究具有不同的设计，然而，普遍的结论是，去氧肾上腺素的疗效是有限的。安全性评估显示无危及生命的不良事件，常见的副作用包括头痛和轻度不适。总之,这项系统评价表明,口服去氧肾上腺素在缓解成人鼻塞方面并不比安慰剂显著更有效.临床医生应该探索替代治疗方案，考虑到审查的局限性。可能需要进一步的研究来阐明口服去氧肾上腺素在控制鼻塞中的作用。
